Mahip Acharya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mahip Acharya has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Bradley C. Martin
Division of Pharmaceutical Evaluation and Policy, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
5 shared publications Corey J. Hayes
Institute for Digital Health & Innovation University of Arkansas for Medical Sciences Little Rock Arkansas USA
4 shared publicationsChenghui Li
Division of Pharmaceutical Evaluation and Policy, Department of Pharmacy Practice, University of Arkansas for Medical Sciences , Little Rock, AR 72205
3 shared publications- Corey J. Hayes
Institute for Digital Health and Innovation, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
3 shared publications Hari Eswaran
Institute for Digital Health & Innovation, University of Arkansas for Medical Sciences, Little Rock, United States
3 shared publicationsLindsey Dayer
College of Pharmacy, University of Arkansas for Medical Sciences , Little Rock, AR 72205
3 shared publications
Latest Publications
- 10 August 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (11) , 10867-10877
Prescribed but Not Filled: Patient Factors Related to Semaglutide/Tirzepatide Prescription Fills Among Those With Prescription Orders for Obesity Treatment
- 10 August 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (11) , 10867-10877
Prescribed but Not Filled: Patient Factors Related to Semaglutide/Tirzepatide Prescription Fills Among Those With Prescription Orders for Obesity Treatment
- 16 July 2026
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 71 (5) , 108508
State X-Waiver Statutes and Buprenorphine Prescriber Rates After Federal X-Waiver Elimination, 2021−2023
- 16 July 2026
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 71 (5) , 108508
State X-Waiver Statutes and Buprenorphine Prescriber Rates After Federal X-Waiver Elimination, 2021−2023
- Open Access
- 30 April 2026
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 26 (1)
Social determinants of health diagnosis codes in in-person and telehealth visits during pregnancy in the United States, 2020–2025: a repeated cross-sectional and case-control study
Social determinants of health (SDoH) diagnosis codes (also known as Z-codes) are used to document patients’ SDoH, which could affect a patient’
- 30 April 2026
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 26 (1)
Open AccessSocial determinants of health diagnosis codes in in-person and telehealth visits during pregnancy in the United States, 2020–2025: a repeated cross-sectional and case-control study
Social determinants of health (SDoH) diagnosis codes (also known as Z-codes) are used to document patients’ SDoH, which could affect a patient’
- Open Access
- 1 March 2026
- Published by SAGE Publications in Women's Health Reports
- Vol. 7
Healthcare trajectories after an initial diagnosis for mood/anxiety disorders via telehealth versus in-person visit among pregnant women without pre-existing mood/anxiety disorders: Latent growth analyses of electronic medical records
Background: With telehealth commonly used for mental health diagnosis and management during pregnancy, it is unknown how it affects utilization trajectories. Methods: We conducted a retrospective cohort study using a national database of electronic medical records (Epic Cosmos), January 2018–November 2025, among pregnant women without pre-existing anxiety, depression, or bipolar disorders. The initial in-person outpatient or telehealth visit/date during pregnancy with a diagnosis of anxiety/depression/bipolar was considered index visit/date. The sample was followed from the index date for 360 days. Four outcomes with anxiety/depression/bipolar diagnoses were studied for each 30-day follow-up interval: 1) emergency department (ED) visits, 2) hospitalizations, 3) in-person outpatient/office visits, and 4) telehealth visits. Multigroup latent growth models were estimated. Average marginal effects (AME) were reported. Results: The final sample had 121,818 in-person outpatient and 7,763 telehealth initiators. The average ages were 28.9 years (in-person) and 30.2 years (telehealth); 84% (in-person) and 87% (telehealth) were urban residents. The AMEs of telehealth use for ED visits and hospitalizations were (in percentage points), respectively, -0.128 (-0.216; -0.040) and -0.222 (-0.432; -0.012). Telehealth initiators were less likely to have in-person outpatient visits (AME: -3.607 (-4.028; -3.185)) and more likely to have telehealth visits (AME: 2.741 (2.380; 3.102)). Conclusion: The initial diagnosis of anxiety, depression, or bipolar conditions via telehealth was associated with similar rates of ED visits and hospitalizations, lower rates of outpatient visits, and higher rates of subsequent telehealth visits.
- 1 March 2026
- Published by SAGE Publications in Women's Health Reports
- Vol. 7
Open AccessHealthcare trajectories after an initial diagnosis for mood/anxiety disorders via telehealth versus in-person visit among pregnant women without pre-existing mood/anxiety disorders: Latent growth analyses of electronic medical records
Background: With telehealth commonly used for mental health diagnosis and management during pregnancy, it is unknown how it affects utilization trajectories. Methods: We conducted a retrospective cohort study using a national database of electronic medical records (Epic Cosmos), January 2018–November 2025, among pregnant women without pre-existing anxiety, depression, or bipolar disorders. The initial in-person outpatient or telehealth visit/date during pregnancy with a diagnosis of anxiety/depression/bipolar was considered index visit/date. The sample was followed from the index date for 360 days. Four outcomes with anxiety/depression/bipolar diagnoses were studied for each 30-day follow-up interval: 1) emergency department (ED) visits, 2) hospitalizations, 3) in-person outpatient/office visits, and 4) telehealth visits. Multigroup latent growth models were estimated. Average marginal effects (AME) were reported. Results: The final sample had 121,818 in-person outpatient and 7,763 telehealth initiators. The average ages were 28.9 years (in-person) and 30.2 years (telehealth); 84% (in-person) and 87% (telehealth) were urban residents. The AMEs of telehealth use for ED visits and hospitalizations were (in percentage points), respectively, -0.128 (-0.216; -0.040) and -0.222 (-0.432; -0.012). Telehealth initiators were less likely to have in-person outpatient visits (AME: -3.607 (-4.028; -3.185)) and more likely to have telehealth visits (AME: 2.741 (2.380; 3.102)). Conclusion: The initial diagnosis of anxiety, depression, or bipolar conditions via telehealth was associated with similar rates of ED visits and hospitalizations, lower rates of outpatient visits, and higher rates of subsequent telehealth visits.
- Open Access
Development, calibration, and external validation of a semi-Markov model for hypertension in older adults with Medicare coverage in the United States
Objective: To develop a semi-Markov model of hypertension specifically using estimates from primary analysis of Medicare data, and calibrate and validate using external trial and observational data. Methods: A semi-Markov model of hypertension with ten disease states was developed using clinical expertise and literature review: hypertension, myocardial infarction (MI), congestive heart failure (CHF), stroke, transient ischemic attack (TIA), other cardiovascular disease (CVD), chronic CVD, early-stage chronic kidney disease (ES CKD), late-stage CKD (LS CKD), and death. Most transition probabilities and hazard ratios for excess mortality were obtained from analysis of Medicare data (2018–2021). Transition probabilities and hazard ratios were calibrated against findings from the Systolic Hypertension in the Elderly Program (SHEP) trial and post-trial follow-up studies. Iterative grid search using Latin Hypercube Sampling was used for calibration, followed by a recalibration using Nelder-Mead simplex method with common random numbers. External validation was performed using mortality data after MI and stroke. Results: Final monthly transition probabilities from hypertension to other states were: other CVD (0.026), ES CKD (0.010), CHF (0.004), stroke (0.004), TIA (0.002), and MI (0.002). Final hazard ratios were: MI (3.29), CHF (3.99), stroke (3.79), TIA (1.39), other CVD (3.84), chronic CVD (1.39), ES CKD (1.24), and LS CKD (4.16). In the external validation, mortality rates per 100 person-years among stroke survivors were 7.8 (modeled) and 8.2 (observed). Conclusion: Our model was reasonably calibrated except for CHF incidence and stroke-related mortality. External validation showed the model performed well over longer timeframe, but discrepancies were observed for shorter periods.
Open AccessDevelopment, calibration, and external validation of a semi-Markov model for hypertension in older adults with Medicare coverage in the United States
Objective: To develop a semi-Markov model of hypertension specifically using estimates from primary analysis of Medicare data, and calibrate and validate using external trial and observational data. Methods: A semi-Markov model of hypertension with ten disease states was developed using clinical expertise and literature review: hypertension, myocardial infarction (MI), congestive heart failure (CHF), stroke, transient ischemic attack (TIA), other cardiovascular disease (CVD), chronic CVD, early-stage chronic kidney disease (ES CKD), late-stage CKD (LS CKD), and death. Most transition probabilities and hazard ratios for excess mortality were obtained from analysis of Medicare data (2018–2021). Transition probabilities and hazard ratios were calibrated against findings from the Systolic Hypertension in the Elderly Program (SHEP) trial and post-trial follow-up studies. Iterative grid search using Latin Hypercube Sampling was used for calibration, followed by a recalibration using Nelder-Mead simplex method with common random numbers. External validation was performed using mortality data after MI and stroke. Results: Final monthly transition probabilities from hypertension to other states were: other CVD (0.026), ES CKD (0.010), CHF (0.004), stroke (0.004), TIA (0.002), and MI (0.002). Final hazard ratios were: MI (3.29), CHF (3.99), stroke (3.79), TIA (1.39), other CVD (3.84), chronic CVD (1.39), ES CKD (1.24), and LS CKD (4.16). In the external validation, mortality rates per 100 person-years among stroke survivors were 7.8 (modeled) and 8.2 (observed). Conclusion: Our model was reasonably calibrated except for CHF incidence and stroke-related mortality. External validation showed the model performed well over longer timeframe, but discrepancies were observed for shorter periods.
- 19 November 2024
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 73 (3) , 966-969
Attrition of remote patient monitoring use for hypertension management in Medicare fee‐for‐service beneficiaries (2018–2021)
- 19 November 2024
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 73 (3) , 966-969
Attrition of remote patient monitoring use for hypertension management in Medicare fee‐for‐service beneficiaries (2018–2021)
- 18 January 2024
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 25 (3) , 173-186
Opioid therapy trajectories of patients with chronic non-cancer pain over 1 year of follow-up after initiation of short-acting opioid formulations
This study compared opioid utilization trajectories of persons initiating tramadol, short-acting hydrocodone, or short-acting oxycodone, and it characterized opioid dose trajectories and type of opioid in persistent opioid therapy subsamples. A retrospective cohort study of adults with chronic non-cancer pain who were initiating opioid therapy was conducted with the IQVIA PharMetrics® Plus for Academics data (2008–2018). Continuous enrollment was required for 6 months before (“baseline”) and 12 months after (“follow-up”) the first opioid prescription (“index date”). Opioid therapy measures were assessed every 7 days over follow-up. Group-based trajectory modeling (GBTM) was used to identify trajectories for any opioid and total morphine milligram equivalent measures, and longitudinal latent class analysis was used for opioid therapy type. A total of 40 276 tramadol, 141 023 hydrocodone, and 45 221 oxycodone initiators were included. GBTM on any opioid therapy identified 3 latent trajectories: early discontinuers (tramadol 39.0%, hydrocodone 54.1%, oxycodone 61.4%), late discontinuers (tramadol 37.9%, hydrocodone 39.4%, oxycodone 33.3%), and persistent therapy (tramadol 6.7%, hydrocodone 6.5%, oxycodone 5.3%). An additional fourth trajectory, intermittent therapy (tramadol 16.4%), was identified for tramadol initiators. Of those on persistent therapy, 2687 individuals were on persistent therapy with tramadol, 9169 with hydrocodone, and 2377 with oxycodone. GBTM on opioid dose resulted in 6 similar trajectory groups in each persistent therapy group. Longitudinal latent class analysis on opioid therapy type identified 6 latent classes for tramadol and oxycodone and 7 classes for hydrocodone. Opioid therapy patterns meaningfully differed by the initial opioid prescribed, notably the presence of intermittent therapy among tramadol initiators and higher morphine milligram equivalents and prescribing of long-acting opioids among oxycodone initiators.
- 18 January 2024
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 25 (3) , 173-186
Opioid therapy trajectories of patients with chronic non-cancer pain over 1 year of follow-up after initiation of short-acting opioid formulations
This study compared opioid utilization trajectories of persons initiating tramadol, short-acting hydrocodone, or short-acting oxycodone, and it characterized opioid dose trajectories and type of opioid in persistent opioid therapy subsamples. A retrospective cohort study of adults with chronic non-cancer pain who were initiating opioid therapy was conducted with the IQVIA PharMetrics® Plus for Academics data (2008–2018). Continuous enrollment was required for 6 months before (“baseline”) and 12 months after (“follow-up”) the first opioid prescription (“index date”). Opioid therapy measures were assessed every 7 days over follow-up. Group-based trajectory modeling (GBTM) was used to identify trajectories for any opioid and total morphine milligram equivalent measures, and longitudinal latent class analysis was used for opioid therapy type. A total of 40 276 tramadol, 141 023 hydrocodone, and 45 221 oxycodone initiators were included. GBTM on any opioid therapy identified 3 latent trajectories: early discontinuers (tramadol 39.0%, hydrocodone 54.1%, oxycodone 61.4%), late discontinuers (tramadol 37.9%, hydrocodone 39.4%, oxycodone 33.3%), and persistent therapy (tramadol 6.7%, hydrocodone 6.5%, oxycodone 5.3%). An additional fourth trajectory, intermittent therapy (tramadol 16.4%), was identified for tramadol initiators. Of those on persistent therapy, 2687 individuals were on persistent therapy with tramadol, 9169 with hydrocodone, and 2377 with oxycodone. GBTM on opioid dose resulted in 6 similar trajectory groups in each persistent therapy group. Longitudinal latent class analysis on opioid therapy type identified 6 latent classes for tramadol and oxycodone and 7 classes for hydrocodone. Opioid therapy patterns meaningfully differed by the initial opioid prescribed, notably the presence of intermittent therapy among tramadol initiators and higher morphine milligram equivalents and prescribing of long-acting opioids among oxycodone initiators.
- 30 December 2022
- Published by Wolters Kluwer Health in The Clinical Journal of Pain
- Vol. 39 (3) , 107-118
Comparative Study of Opioid Initiation With Tramadol, Short-acting Hydrocodone, or Short-acting Oxycodone on Opioid-related Adverse Outcomes Among Chronic Noncancer Pain Patients
Objective: To compare the safety profiles of low and high-dose tramadol, short-acting hydrocodone, and short-acting oxycodone therapies among chronic noncancer pain individuals. Materials and Methods: A retrospective cohort study of individuals with back/neck pain/osteoarthritis with an initial opioid prescription for tramadol, hydrocodone, or oxycodone was conducted using IQVIA PharMetrics Plus claims for Academics database (2006 to 2020). Two cohorts were created for separately studying opioid-related adverse events (overdoses, accidents, self-inflicted injuries, and violence-related injuries) and substance use disorders (opioid and nonopioid). Patients were followed from the index date until an outcome event, end of enrollment, or data end. Time-varying exposure groups were constructed and Cox regression models were estimated. Results: A total of 1,062,167 (tramadol [16.5%], hydrocodone [61.1%], and oxycodone [22.4%]) and 986,809 (tramadol [16.5%], hydrocodone [61.3%], and oxycodone [22.2%]) individuals were in the adverse event and substance use disorder cohorts. All high-dose groups had elevated risk of nearly all outcomes, compared with low-dose hydrocodone. Compared with low-dose hydrocodone, low-dose oxycodone was associated with a higher risk of opioid overdose (hazard ratio: 1.79 [1.37 to 2.33]). No difference in risk was observed between low-dose tramadol and low-dose hydrocodone (hazard ratio: 0.85 [0.64 to 1.13]). Low-dose oxycodone had higher risks of an opioid use disorder, and low-dose tramadol had a lower risk of accidents, self-inflicted injuries, and opioid use disorder compared with low-dose hydrocodone. Discussion: Low-dose oxycodone had a higher risk of opioid-related adverse outcomes compared with low-dose tramadol and hydrocodone. This should be interpreted in conjunction with the benefits of pain control and functioning associated with oxycodone use in future research.
- 30 December 2022
- Published by Wolters Kluwer Health in The Clinical Journal of Pain
- Vol. 39 (3) , 107-118
Comparative Study of Opioid Initiation With Tramadol, Short-acting Hydrocodone, or Short-acting Oxycodone on Opioid-related Adverse Outcomes Among Chronic Noncancer Pain Patients
Objective: To compare the safety profiles of low and high-dose tramadol, short-acting hydrocodone, and short-acting oxycodone therapies among chronic noncancer pain individuals. Materials and Methods: A retrospective cohort study of individuals with back/neck pain/osteoarthritis with an initial opioid prescription for tramadol, hydrocodone, or oxycodone was conducted using IQVIA PharMetrics Plus claims for Academics database (2006 to 2020). Two cohorts were created for separately studying opioid-related adverse events (overdoses, accidents, self-inflicted injuries, and violence-related injuries) and substance use disorders (opioid and nonopioid). Patients were followed from the index date until an outcome event, end of enrollment, or data end. Time-varying exposure groups were constructed and Cox regression models were estimated. Results: A total of 1,062,167 (tramadol [16.5%], hydrocodone [61.1%], and oxycodone [22.4%]) and 986,809 (tramadol [16.5%], hydrocodone [61.3%], and oxycodone [22.2%]) individuals were in the adverse event and substance use disorder cohorts. All high-dose groups had elevated risk of nearly all outcomes, compared with low-dose hydrocodone. Compared with low-dose hydrocodone, low-dose oxycodone was associated with a higher risk of opioid overdose (hazard ratio: 1.79 [1.37 to 2.33]). No difference in risk was observed between low-dose tramadol and low-dose hydrocodone (hazard ratio: 0.85 [0.64 to 1.13]). Low-dose oxycodone had higher risks of an opioid use disorder, and low-dose tramadol had a lower risk of accidents, self-inflicted injuries, and opioid use disorder compared with low-dose hydrocodone. Discussion: Low-dose oxycodone had a higher risk of opioid-related adverse outcomes compared with low-dose tramadol and hydrocodone. This should be interpreted in conjunction with the benefits of pain control and functioning associated with oxycodone use in future research.
- 22 December 2022
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 63 (2) , 648-654.e3
Evaluating the temporal association between the recency of prescribed controlled substance acquisition and fatal and non-fatal opioid overdose
- 22 December 2022
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 63 (2) , 648-654.e3
Evaluating the temporal association between the recency of prescribed controlled substance acquisition and fatal and non-fatal opioid overdose
- 16 December 2022
- Published by SAGE Publications in Population Health Management
- Vol. 25 (6) , 798-806
Association Between Broadband Capacity and Social Vulnerability Factors in the United States: A County-Level Spatial Analysis
This study evaluated relationships between county-level social vulnerability and broadband access using spatial clustering and regression approaches. County-level broadband availability (Federal Communications Commission [FCC] and Microsoft; 2019–2020), social vulnerability (COVID-19 Community Vulnerability Index [CCVI]; 2020), and primary care access (Area Health Resource File; 2019–2020) data sets were used. Two measures of broadband availability were considered: (1) Microsoft system-reported proportion of county population with broadband and (2) difference in FCC-reported and Microsoft-reported proportions of county population with broadband. Cluster maps were constructed using local Moran's I, and spatial Durbin models were estimated using primary care shortage designation and CCVI themes (socioeconomic status, minority status, housing/transportation/disability, epidemiological risk, health care system, high-risk environment, and population density). Among 3102 counties, county-level broadband coverage varied widely between Microsoft (0.39) and FCC (0.84), with greater coverage in the East and West, and larger discrepancies between FCC and Microsoft data in the South and Appalachia. In spatial regressions, a one-point increase in socioeconomic status vulnerability (0—least; 10—most vulnerable), was associated with a 2.0 percentage point (pp) reduction in broadband access ( P < 0.001). Similar inverse relationships were observed with housing, epidemiological, and health care system variables. There were greater divergences between FCC and Microsoft measures with each one-point increase in socioeconomic status (1.4 pp), epidemiological risk (0.6 pp), and health care system (0.7 pp) vulnerability. More vulnerable counties had lower broadband and larger divergences between FCC and Microsoft data. Broadband is necessary for utilizing telehealth services; careful considerations in measuring broadband access can facilitate policies that improve equitable access to care.
- 16 December 2022
- Published by SAGE Publications in Population Health Management
- Vol. 25 (6) , 798-806
Association Between Broadband Capacity and Social Vulnerability Factors in the United States: A County-Level Spatial Analysis
This study evaluated relationships between county-level social vulnerability and broadband access using spatial clustering and regression approaches. County-level broadband availability (Federal Communications Commission [FCC] and Microsoft; 2019–2020), social vulnerability (COVID-19 Community Vulnerability Index [CCVI]; 2020), and primary care access (Area Health Resource File; 2019–2020) data sets were used. Two measures of broadband availability were considered: (1) Microsoft system-reported proportion of county population with broadband and (2) difference in FCC-reported and Microsoft-reported proportions of county population with broadband. Cluster maps were constructed using local Moran's I, and spatial Durbin models were estimated using primary care shortage designation and CCVI themes (socioeconomic status, minority status, housing/transportation/disability, epidemiological risk, health care system, high-risk environment, and population density). Among 3102 counties, county-level broadband coverage varied widely between Microsoft (0.39) and FCC (0.84), with greater coverage in the East and West, and larger discrepancies between FCC and Microsoft data in the South and Appalachia. In spatial regressions, a one-point increase in socioeconomic status vulnerability (0—least; 10—most vulnerable), was associated with a 2.0 percentage point (pp) reduction in broadband access ( P < 0.001). Similar inverse relationships were observed with housing, epidemiological, and health care system variables. There were greater divergences between FCC and Microsoft measures with each one-point increase in socioeconomic status (1.4 pp), epidemiological risk (0.6 pp), and health care system (0.7 pp) vulnerability. More vulnerable counties had lower broadband and larger divergences between FCC and Microsoft data. Broadband is necessary for utilizing telehealth services; careful considerations in measuring broadband access can facilitate policies that improve equitable access to care.